Literature DB >> 19806612

PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells.

Stéphanie Bougel1, Stéphanie Renaud, Richard Braunschweig, Dmitri Loukinov, Herbert C Morse, Fred T Bosman, Victor Lobanenkov, Jean Benhattar.   

Abstract

Telomerase is an RNA-dependent DNA polymerase that synthesizes telomeric DNA. Its activity is not detectable in most somatic cells but it is reactivated during tumorigenesis. In most cancers, the combination of hTERT hypermethylation and hypomethylation of a short promoter region is permissive for low-level hTERT transcription. Activated and malignant lymphocytes express high telomerase activity, through a mechanism that seems methylation-independent. The aim of this study was to determine which mechanism is involved in the enhanced expression of hTERT in lymphoid cells. Our data confirm that in B cells, some T cell lymphomas and non-neoplastic lymph nodes, the hTERT promoter is unmethylated. Binding sites for the B cell-specific transcription factor PAX5 were identified downstream of the ATG translational start site through EMSA and ChIP experiments. ChIP assays indicated that the transcriptional activation of hTERT by PAX5 does not involve repression of CTCF binding. In a B cell lymphoma cell line, siRNA-induced knockdown of PAX5 expression repressed hTERT transcription. Moreover, ectopic expression of PAX5 in a telomerase-negative normal fibroblast cell line was found to be sufficient to activate hTERT expression. These data show that activation of hTERT in telomerase-positive B cells is due to a methylation-independent mechanism in which PAX5 plays an important role.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19806612      PMCID: PMC3422366          DOI: 10.1002/path.2620

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  45 in total

Review 1.  A PANorama of PAX genes in cancer and development.

Authors:  Ewan J D Robson; Shu-Jie He; Michael R Eccles
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

2.  A methylation sensitive dot blot assay (MS-DBA) for the quantitative analysis of DNA methylation in clinical samples.

Authors:  G Clément; J Benhattar
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

3.  Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function.

Authors:  Alexandra Schebesta; Shane McManus; Giorgia Salvagiotto; Alessio Delogu; Georg A Busslinger; Meinrad Busslinger
Journal:  Immunity       Date:  2007-07-19       Impact factor: 31.745

4.  hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site.

Authors:  Rebekah L Zinn; Kevin Pruitt; Sayaka Eguchi; Stephen B Baylin; James G Herman
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

5.  Methylation-sensitive, single-strand conformation analysis (MS-SSCA): A rapid method to screen for and analyze methylation.

Authors:  T Bianco; D Hussey; A Dobrovic
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

6.  Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.

Authors:  Paulette Mhawech-Fauceglia; Rhakee Saxena; Shaozeng Zhang; Luigi Terracciano; Guido Sauter; Arundhuti Chadhuri; Francois R Herrmann; Remedios Penetrante
Journal:  J Clin Pathol       Date:  2006-07-12       Impact factor: 3.411

7.  Familial cases of point mutations in the XIST promoter reveal a correlation between CTCF binding and pre-emptive choices of X chromosome inactivation.

Authors:  Elena M Pugacheva; Vijay Kumar Tiwari; Ziedulla Abdullaev; Alexander A Vostrov; Patrick T Flanagan; Wolfgang W Quitschke; Dmitri I Loukinov; Rolf Ohlsson; Victor V Lobanenkov
Journal:  Hum Mol Genet       Date:  2005-02-24       Impact factor: 6.150

8.  The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms.

Authors:  Kristin C Jensen; John P T Higgins; Kelli Montgomery; Gulsah Kaygusuz; Matt van de Rijn; Yasodha Natkunam
Journal:  Mod Pathol       Date:  2007-05-25       Impact factor: 7.842

9.  CTCF binds the proximal exonic region of hTERT and inhibits its transcription.

Authors:  Stéphanie Renaud; Dmitri Loukinov; Fred T Bosman; Victor Lobanenkov; Jean Benhattar
Journal:  Nucleic Acids Res       Date:  2005-12-02       Impact factor: 16.971

10.  Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene.

Authors:  S Renaud; D Loukinov; Z Abdullaev; I Guilleret; F T Bosman; V Lobanenkov; J Benhattar
Journal:  Nucleic Acids Res       Date:  2007-01-31       Impact factor: 16.971

View more
  12 in total

1.  Transcriptional effects of a lupus-associated polymorphism in the 5' untranslated region (UTR) of human complement receptor 2 (CR2/CD21).

Authors:  Mark N Cruickshank; Mahdad Karimi; Rhonda L Mason; Emily Fenwick; Tim Mercer; Betty P Tsao; Susan A Boackle; Daniela Ulgiati
Journal:  Mol Immunol       Date:  2012-06-04       Impact factor: 4.407

2.  New developments in the pathology of malignant lymphoma: a review of the literature published from August to November 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-12-17       Impact factor: 0.196

3.  BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells.

Authors:  Stéphanie Renaud; Dmitri Loukinov; Loredana Alberti; Alexander Vostrov; Yoo-Wook Kwon; Fred T Bosman; Victor Lobanenkov; Jean Benhattar
Journal:  Nucleic Acids Res       Date:  2010-09-28       Impact factor: 16.971

4.  Molecular Mechanism of Telomere Length Dynamics and Its Prognostic Value in Pediatric Cancers.

Authors:  Zhaoming Wang; Stephen V Rice; Ti-Cheng Chang; Yu Liu; Qi Liu; Na Qin; Daniel K Putnam; Kyla Shelton; Jennifer Q Lanctot; Carmen L Wilson; Kirsten K Ness; Michael C Rusch; Michael N Edmonson; Gang Wu; John Easton; Chimene A Kesserwan; James R Downing; Xiang Chen; Kim E Nichols; Yutaka Yasui; Leslie L Robison; Jinghui Zhang
Journal:  J Natl Cancer Inst       Date:  2020-07-01       Impact factor: 11.816

5.  Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.

Authors:  S Kasar; C Underbayev; Y Yuan; M Hanlon; S Aly; H Khan; V Chang; M Batish; T Gavrilova; F Badiane; H Degheidy; G Marti; E Raveche
Journal:  Oncogene       Date:  2013-09-02       Impact factor: 9.867

6.  Recombinant lentivirus with enhanced expression of caudal-related homeobox protein 2 inhibits human colorectal cancer cell proliferation in vitro.

Authors:  Sai He; Xue-Jun Sun; Jian-Bao Zheng; Jie Qi; Nan-Zheng Chen; Wei Wang; Guang-Bing Wei; Dong Liu; Jun-Hui Yu; Shao-Ying Lu; Hui Wang
Journal:  Mol Med Rep       Date:  2015-04-03       Impact factor: 2.952

7.  Targeted CDX2 expression inhibits aggressive phenotypes of colon cancer cells in vitro and in vivo.

Authors:  Jianbao Zheng; Sai He; Jie Qi; Xiaolong Wang; Junhui Yu; Yunhua Wu; Qi Gao; Kai Wang; Xuejun Sun
Journal:  Int J Oncol       Date:  2017-06-13       Impact factor: 5.650

8.  Multiple tumor suppressor microRNAs regulate telomerase and TCF7, an important transcriptional regulator of the Wnt pathway.

Authors:  Radmila Hrdličková; Jiří Nehyba; William Bargmann; Henry R Bose
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

Review 9.  Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene.

Authors:  Muhammad Khairul Ramlee; Jing Wang; Wei Xun Toh; Shang Li
Journal:  Genes (Basel)       Date:  2016-08-18       Impact factor: 4.096

10.  Telomerase reverse transcriptase methylation predicts lymph node metastasis and prognosis in patients with gastric cancer.

Authors:  Yongxin Wu; Guichao Li; Dong He; Fengping Yang; Guang He; Lin He; Hui Zhang; Yun Deng; Ming Fan; Lijun Shen; Daizhan Zhou; Zhen Zhang
Journal:  Onco Targets Ther       Date:  2016-01-11       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.